507 related articles for article (PubMed ID: 25824054)
1. Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets.
von Büdingen HC; Palanichamy A; Lehmann-Horn K; Michel BA; Zamvil SS
Eur Neurol; 2015; 73(3-4):238-246. PubMed ID: 25824054
[TBL] [Abstract][Full Text] [Related]
2. CD20 therapies in multiple sclerosis and experimental autoimmune encephalomyelitis - Targeting T or B cells?
Agahozo MC; Peferoen L; Baker D; Amor S
Mult Scler Relat Disord; 2016 Sep; 9():110-7. PubMed ID: 27645355
[TBL] [Abstract][Full Text] [Related]
3. Therapies for multiple sclerosis targeting B cells.
Milo R
Croat Med J; 2019 Apr; 60(2):87-98. PubMed ID: 31044580
[TBL] [Abstract][Full Text] [Related]
4. B cells in multiple sclerosis therapy-A comprehensive review.
Rahmanzadeh R; Weber MS; Brück W; Navardi S; Sahraian MA
Acta Neurol Scand; 2018 Jun; 137(6):544-556. PubMed ID: 29512131
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.
Dunn N; Juto A; Ryner M; Manouchehrinia A; Piccoli L; Fink K; Piehl F; Fogdell-Hahn A
Mult Scler; 2018 Aug; 24(9):1224-1233. PubMed ID: 28762877
[TBL] [Abstract][Full Text] [Related]
6. B cell-directed therapies in multiple sclerosis.
Gasperi C; Stüve O; Hemmer B
Neurodegener Dis Manag; 2016; 6(1):37-47. PubMed ID: 26782316
[TBL] [Abstract][Full Text] [Related]
7. B cell depletion in the treatment of multiple sclerosis.
Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
[TBL] [Abstract][Full Text] [Related]
8. B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.
Kinzel S; Weber MS
CNS Drugs; 2016 Dec; 30(12):1137-1148. PubMed ID: 27844213
[TBL] [Abstract][Full Text] [Related]
9. Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis.
Chen D; Ireland SJ; Davis LS; Kong X; Stowe AM; Wang Y; White WI; Herbst R; Monson NL
J Immunol; 2016 Feb; 196(4):1541-9. PubMed ID: 26764035
[TBL] [Abstract][Full Text] [Related]
10. B-Cell-Directed Therapies: A New Era in Multiple Sclerosis Treatment.
Kanatas P; Stouras I; Stefanis L; Stathopoulos P
Can J Neurol Sci; 2023 May; 50(3):355-364. PubMed ID: 35570581
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic strategies targeting B-cells in multiple sclerosis.
Milo R
Autoimmun Rev; 2016 Jul; 15(7):714-8. PubMed ID: 26970489
[TBL] [Abstract][Full Text] [Related]
12. Development of anti-CD20 therapy for multiple sclerosis.
Bartok B; Silverman GJ
Exp Cell Res; 2011 May; 317(9):1312-8. PubMed ID: 21510932
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis.
Sellebjerg F; Blinkenberg M; Sorensen PS
CNS Drugs; 2020 Mar; 34(3):269-280. PubMed ID: 31994023
[TBL] [Abstract][Full Text] [Related]
14. Targeting CD20 in multiple sclerosis - review of current treatment strategies.
Chmielewska N; Szyndler J
Neurol Neurochir Pol; 2023; 57(3):235-242. PubMed ID: 36999373
[TBL] [Abstract][Full Text] [Related]
15. B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases.
Uzzan M; Colombel JF; Cerutti A; Treton X; Mehandru S
Dig Dis Sci; 2016 Dec; 61(12):3407-3424. PubMed ID: 27655102
[TBL] [Abstract][Full Text] [Related]
16. B-cell-targeted therapy for systemic lupus erythematosus.
Sabahi R; Anolik JH
Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
[TBL] [Abstract][Full Text] [Related]
17. Obinutuzumab-Induced B Cell Depletion Reduces Spinal Cord Pathology in a CD20 Double Transgenic Mouse Model of Multiple Sclerosis.
Breakell T; Tacke S; Schropp V; Zetterberg H; Blennow K; Urich E; Kuerten S
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962135
[TBL] [Abstract][Full Text] [Related]
18. Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives.
D'Amico E; Zanghì A; Gastaldi M; Patti F; Zappia M; Franciotta D
Autoimmun Rev; 2019 Jul; 18(7):665-672. PubMed ID: 31059839
[TBL] [Abstract][Full Text] [Related]
19. Effector and regulatory B cells in Multiple Sclerosis.
Staun-Ram E; Miller A
Clin Immunol; 2017 Nov; 184():11-25. PubMed ID: 28461106
[TBL] [Abstract][Full Text] [Related]
20. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.
Ancau M; Berthele A; Hemmer B
Expert Opin Biol Ther; 2019 Aug; 19(8):829-843. PubMed ID: 31027436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
